Qianhe Capital

The firm operates a multistage private equity mandate that covers seed, start-up, early-stage, expansion, and growth investments, according to its regulatory classification. This span suggests it can participate across the company lifecycle, though no public filings confirm check-size ranges, sector focuses, or geographic limits beyond mainland China. Allocators evaluating the firm should treat the broad mandate as indicative rather than empirically verified by disclosed deals.

No named principals, investment committee members, or key executives are disclosed in the firm's public record. The absence of identified leadership makes it impossible to assess individual track records, turnover risk, or decision-making structure from outside sources. Any due diligence process would need to source this information directly from the firm.

No public disclosures of assets under management, fund sizes, or aggregate deployment are available. The firm does not appear in major databases, press coverage, or regulatory filings that report fund-level capital commitments. This opacity is common among smaller private fund managers in China who raise capital from a tight domestic LP base without publishing fund closes.

No sector tags or investment themes are publicly attributed to the firm. Unlike peers who concentrate on hard tech, healthcare, or consumer verticals, Qianhe Capital's available records reflect a generalist posture. Without named portfolio companies or stated exclusion criteria, no concentration can be inferred.

The path is onshore-primary only. An allocator would need direct access to the firm's partnership for organizational documents, fund formation records, and track record data, alongside references from domestic Chinese intermediaries or existing LPs. Given the absence of English-language press, fund databases, or marketing materials, offshore due diligence from public sources alone cannot produce an independent asset under management figure, team bios, or verified performance metrics.